Antimicrobial Resistance. The Fight Just Got Real.

A new state of the art institute for antimicrobial research is to open at the University of Oxford thanks to a £100 million donation from INEOS

The donation will allow the institute to work towards combating the growing global issue of antimicrobial resistance (AMR), which currently causes an estimated 1.5 million excess deaths each year- and could cause over 10m deaths per year by 2050.

The world is fast running out of effective antibiotics as bacteria evolve to develop resistance to our taken-for-granted treatments. Without urgent collaborative action to prevent common microbes from becoming multi-drug resistant, we could return to a world where treatments such as chemotherapy and hip replacements could become too risky, childbirth becomes extremely dangerous, and even a basic scratch could kill.

Professor Louise Richardson, Vice-Chancellor at the said: “Oxford played a crucial role in the early development of antibiotics so it is only appropriate that we take the lead in developing a solution to antimicrobial resistance.”

It’s great news for Oxford and humanity.

Read the full press release here:

https://lnkd.in/gECWS_4

Additional News

  • 22 června 2023

    Quinta Analytica Partners with EvidentIQ to Enhance Efficiency of Phase 1 Studies

    EvidentIQ partners with Quinta-Analytica to enhance Phase 1 study efficiency

  • 15 června 2023

    Novavax & Conscio: Behind the Scenes of Vaccine Development

    Discover how the Conscio Group and renowned vaccine manufacturer Novavax collaborate behind the scenes to ensure quality and efficiency in vaccine production.

  • 8 června 2023

    Clinical Tips – Drug Interactions in Advanced Clinical Trial Design

    Drug interactions play a key role in the design of clinical trials. Learn how we investigate such interactions when conducting pharmacokinetic/bioequivalence studies and while offering end-to-end support throughout the process.